View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2014	Aug. 04, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		9,451,930
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2014

Dec. 31, 2013

Current assets

Cash and cash equivalents

$ 27,284

$ 31,249

Accounts receivables, net

172

349

Inventories, net

600

719

Prepaid expenses and other current assets

852

1,711

Total current assets

28,908

34,028

Property, plant and equipment, net

2,421

3,069

Total assets

31,329

37,097

Current liabilities

Accounts payable

239

582

Accrued expenses

4,087

3,740

Warrant liability

1,075

2,310

Total current liabilities

5,401

6,632

Other non-current liabilities

748

366

Total liabilities

6,149

6,998

Commitments and contingencies (Note 11)

Stockholders' equity

Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013

Common stock, $.01 par value; 170,000,000 shares authorized; 9,451,870 and 8,394,397 shares issued and 9,447,392 and 8,392,641 shares outstanding at June 30, 2014 and December 31, 2013, respectively *

^[1]

Additional paid-in capital

264,072

259,102

Accumulated deficit

(239,010)

(229,132)

Treasury stock, at cost; 1,757 shares at June 30, 2014 and December 31, 2013 *

^[1]

(51)

Accumulated other comprehensive income

Total stockholders' equity

25,180

30,099

Total liabilities and stockholders' equity

$ 31,329

$ 37,097

[1]	Reflects a one-for- sixteen (1:16) reverse stock split effected on April 8, 2014.

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	9,451,870	8,394,397
Common stock, shares outstanding (in shares)	9,447,392	8,392,641
Treasury stock, at cost (in shares)	1,757	1,757
Reverse stock split ratio	one-for- sixteen (1:16)	one-for- sixteen (1:16)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

REVENUES

Product revenues

$ 251

$ 0

$ 561

$ 81

Other revenues

300

Total revenues

251

561

381

COSTS OF SALES

Costs of goods sold

(66)

(332)

(160)

(363)

Gross profit

185

(332)

401

OPERATING EXPENSES

Selling, general and administrative

4,597

6,263

8,416

12,346

Research and development

1,492

3,992

2,949

8,462

Total operating expenses

6,089

10,255

11,365

20,808

Loss from operations

(5,904)

(10,587)

(10,964)

(20,790)

OTHER INCOME (EXPENSE)

Change in fair value of warrant liability, net

1,297

5,115

1,092

2,842

Interest income

Other expenses

(15)

(8)

(395)

Net loss

$ (4,600)

$ (5,482)

$ (9,878)

$ (18,328)

LOSS PER COMMON SHARE

Basic loss per common share (in dollars per share)

^[1]

$ (0.49)

$ (0.91)

$ (1.06)

$ (3.22)

Diluted loss per common share (in dollars per share)

^[1]

$ (0.52)

$ (0.91)

$ (1.08)

$ (3.22)

WEIGHTED AVERAGE COMMON SHARES

Basic weighted average common shares outstanding (in shares)

^[1]

9,426,169

6,023,785

9,363,123

5,683,380

Diluted weighted average common shares outstanding (in shares)

^[1]

9,480,933

6,023,785

9,462,717

5,683,380

OTHER COMPREHENSIVE INCOME (LOSS)

Foreign currency translation adjustments

$ (20)

$ 6

$ (22)

$ 369

Comprehensive loss

$ (4,620)

$ (5,476)

$ (9,900)

$ (17,959)

[1]	Reflects a one-for- sixteen (1:16) reverse stock split effected on April 8, 2014.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013	Dec. 31, 2013
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) [Abstract]
Reverse stock split ratio	one-for- sixteen (1:16)	one-for- sixteen (1:16)	one-for- sixteen (1:16)	one-for- sixteen (1:16)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (9,878)	$ (18,328)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	257	571
Restricted stock compensation expense	60	241
Depreciation expense	499	604
Provision for inventory obsolescence	102	17
Warrant liability fair value adjustment	(1,092)	(2,842)
Loss on write-downs and disposals of equipment	123	5
Non-cash interest income	0	1
Changes in assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	856	(132)
Decrease in accounts receivable	183	84
Decrease in inventories	15	157
Increase (decrease) in accounts payable and accrued expenses	7	(1,576)
Increase (decrease) in other non-current liabilities	383	(300)
Net cash used in operating activities	(8,485)	(21,498)
Cash flows from investing activities:
Purchase of property, plant, and equipment	0	(79)
Proceeds from sales of property, plant, and equipment	22	0
Net cash provided by (used in) investing activities	22	(79)
Cash flows from financing activities:
Net proceeds from sale of stock and exercise of stock options and warrants	4,521	29,975
Net cash provided by financing activities	4,521	29,975
Foreign currency effects on cash	(23)	202
Net (decrease) increase in cash and cash equivalents	(3,965)	8,600
Cash and cash equivalents:
Beginning of period	31,249	23,726
End of period	27,284	32,326
Supplemental non-cash activities:
Fair value of warrants exercised	$ 143	$ 219

General

6 Months Ended

Jun. 30, 2014

General [Abstract]

General

(1)

General

The interim Condensed Consolidated Financial Statements of Delcath Systems, Inc. (“Delcath” or the “Company”) for the three and six months ended June 30, 2014 and 2013 should be read in conjunction with the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2013, which has been filed with the Securities Exchange Commission (“SEC”) and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

On April 8, 2014, the Company effected a one-for-sixteen (1:16) reverse stock split. Refer to Note 7 Stockholders’ Equity of these Condensed Consolidated Financial Statements for further information.

Description of Business

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan HDS)—is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company's principal focus is on the treatment of primary and metastatic liver cancers.

In the United States, Melphalan HDS is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). Melphalan HDS has not been approved for sale in the United States. In Europe, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (CHEMOSAT). In April 2012, we obtained authorization to affix a CE Mark for Generation Two CHEMOSAT. The right to affix the CE mark allows the Company to market and sell CHEMOSAT in Europe. The Company has initiated plans to investigate Melphalan HDS for primary liver cancer.

The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations through the first half of 2015, but anticipates that additional working capital may be required to continue operations. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainties and risks related to product development; regulatory approvals; technology; patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing; marketing and sales experience; and dependence on key personnel.

Basis of Presentation

These interim Condensed Consolidated Financial Statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim Condensed Consolidated Financial Statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended June 30, 2014 and 2013; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year.

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in our Annual Report.

Recently Adopted Accounting Pronouncements

In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard became effective for fiscal years beginning after December 15, 2013. The Company adopted this guidance effective January 1, 2014. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company expects to adopt this guidance when effective, and the impact on our financial statements is not currently estimable.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is evaluating the potential impacts of the new standard on its existing stock-based compensation plans.

Inventories

6 Months Ended

Jun. 30, 2014

Inventories [Abstract]

Inventories

(2)	Inventories

Inventories consist of the following:

(in thousands)	June 30, 2014		December 31, 2013
Raw materials	$	196	$	249
Work-in-process		295		364
Finished goods		109		106
Total inventory	$	600	$	719

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses and Other Current Assets

(3)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	June 30, 2014		December 31, 2013
Kits for clinical use	$	327	$	287
Insurance premiums		322		407
Professional fees		27		377
Income tax credits receivable		18		326
Other¹		158		314
Total prepaid expenses and other current assets	$	852	$	1,711

¹ Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at June 30, 2014 and December 31, 2013.

Property, Plant, and Equipment

6 Months Ended

Jun. 30, 2014

Property, Plant, and Equipment [Abstract]

Property, Plant, and Equipment

(4)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

(in thousands)	June 30, 2014			December 31, 2013
Enterprise hardware and software	$	2,009		$	2,143
Leaseholds		1,667			1,749
Equipment		1,421			1,552
Furniture		957			957
Buildings and land		603			603
Property, plant and equipment, gross		6,657			7,004
Accumulated depreciation		(4,236	)		(3,935	)
Property, plant and equipment, net	$	2,421		$	3,069

Depreciation expense for the three and six months ended June 30, 2014 was approximately $0.3 million and $0.5 million, respectively, as compared to approximately $0.3 million and $0.6 million for the same periods in 2013.

Accrued Expenses

6 Months Ended

Jun. 30, 2014

Accrued Expenses [Abstract]

Accrued Expenses

(5)	Accrued Expenses

Accrued expenses consist of the following:

(in thousands)	June 30, 2014		December 31, 2013
Compensation, excluding taxes	$	2,470	$	1,866
Deferred rent		315		485
Professional fees		224		360
Short-term portion of lease restructuring		209		–
Other¹		869		1,029
Total accrued expenses	$	4,087	$	3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at June 30, 2014 and December 31, 2013.

In November 2013, the Board of Directors approved an Employee Retention Program for certain key employees, including the Company’s executive officers. The key employees will be eligible to receive a cash retention bonus payment equal to fifty percent (50%) of their current annual salary if they remain employed by the Company through March 31, 2015. The expense related to this program is being accrued ratably over the required service period and has been included in Accrued expenses on the Condensed Consolidated Balance Sheets and in both Selling, general and administrative and Research and development on the Condensed Consolidated Statements of Operations.

For a description of the Company’s lease restructuring liability refer to Note 6 Restructuring Expenses of these Condensed Consolidated Financial Statements.

Restructuring Expenses

6 Months Ended

Jun. 30, 2014

Restructuring Expenses [Abstract]

Restructuring Expenses

(6)	Restructuring Expenses

During 2013, the Company implemented workforce restructurings to better focus its organizational structure, increase efficiency and concentrate financial resources on its clinical development program and European commercialization activity. This resulted in a total reduction in the Company’s workforce by 50 employees. During the second quarter of 2014, the Company implemented additional workforce restructurings that resulted in a total reduction in the Company’s workforce by seven employees. As a result of termination benefits provided to these 57 employees the Company has incurred a total restructuring charge of approximately $4.8 million for employee related expenses. At June 30, 2014, the remaining restructuring reserve of approximately $1.5 million is included in Accrued expenses and Other non-current liabilities on the Condensed Consolidated Balance Sheets for approximately $1.4 million and $0.1 million, respectively.

In order to more appropriately align its office space with the reduced size of its workforce, during the quarter ended June 30, 2014, the Company implemented a plan to vacate and sub-lease office space at its 810 Seventh Avenue location in New York, NY. On May 22, 2014, the Company entered into a sub-lease agreement for approximately one-half of the office space at this location and had vacated and relinquished the premises to the sub-tenant as of June 30, 2014. At June 30, 2014, future rent obligations for the vacated space under the Company’s Prime Lease over the remaining lease term of 81 months totaled approximately $3.6 million. Under its new sub-lease agreement for the vacated space the Company will receive future sub-lease rental receipts totaling approximately $2.6 million, resulting in net future cash outflows of approximately $1.0 million. In accordance with ASC 420, Exit or Disposal Cost Obligations, the Company calculated the fair value of the remaining net cash flow liability for the vacated space and recorded a lease restructuring reserve of approximately $0.9 million. Additionally, during the quarter ended June 30, 2014, the Company recorded contract termination costs related to the sub-lease of approximately $150,000 and wrote off approximately $50,000 of unamortized leasehold improvements related to the vacated space. The expenses related to this lease restructuring have been recorded in Selling, general and administrative on the Condensed Consolidated Statements of Operations while the fair value of the liability has been included in both Accrued expenses and Other non-current liabilities on the Condensed Consolidated Balance Sheets.

The following table provides the year-to-date activity of the Company’s restructuring reserves as of June 30, 2014:

(in thousands)	Employee Costs			Operating Lease
Reserve balance as of December 31, 2013	$	2,019		$	–
Charges		722			855
Payments / utilizations		(1,287	)		–
Reserve balance as of June 30, 2014	$	1,454		$	855

Stockholders Equity

6 Months Ended

Jun. 30, 2014

Stockholders Equity [Abstract]

Stockholders Equity

(7)	Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On February 24, 2014, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock. The reverse stock split became effective on April 8, 2014 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the close of the NASDAQ market on April 8, 2014 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the number of common shares authorized or the par value per share of Delcath common stock, which remain 170,000,000 and $0.01, respectively. All current and prior period amounts related to shares, share prices and earnings per share, presented in these Condensed Consolidated Financial Statements and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

At-the-Market (“ATM”) Programs

In December 2011, the Company entered into an agreement with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $39.8 million, under which Cowen would act as sales agent. During the first quarter of 2013, the Company sold approximately 14.2 million shares of its common stock under this ATM program for proceeds of approximately $20.9 million, with net cash proceeds after related expenses of approximately $20.8 million, and successfully completed the program. As of March 31, 2013, there were no shares of common stock of the Company remaining for sale under this ATM program.

In March 2013, the Company entered into a new agreement with Cowen to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 1.0 million shares of its common stock under this ATM program for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. During the first quarter of 2014 the Company sold an additional 1.0 million shares of its common stock under this ATM program for proceeds of approximately $4.4 million, with net cash proceeds after related expenses of approximately $4.4 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and working capital. There were no shares of common stock sold under the ATM program during the second quarter of 2014. As of June 30, 2014, the Company has approximately $40.4 million remaining under the program.

Committed Equity Financing Facility (“CEFF”) Program

In December 2012, the Company entered into an agreement with Terrapin Opportunity, L.P. (“Terrapin”) for a CEFF program. Under the agreement Terrapin committed to purchase up to $35.0 million of Delcath common stock over a 24-month term. Since inception, the Company has sold approximately 0.5 million shares of its common stock through the program for total proceeds of approximately $11.1 million, with net cash proceeds after related expenses of approximately $10.8 million. As a result, there was approximately $23.9 million available under this CEFF program as of June 30, 2014. The shares were issued pursuant to an effective registration statement on Form S-3 (333-183675). The net proceeds will be used for general corporate purposes including, but not limited to, commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures and general working capital needs.

Warrants

In June 2009, the Company completed the sale of 0.1 million shares of its common stock and the issuance of warrants to purchase 0.1 million common shares (the “2009 Warrants”) pursuant to a subscription agreement with a single investor. The Company received proceeds of $3.0 million, with net cash proceeds after related expenses from this transaction of approximately $2.7 million. Of those proceeds, the Company allocated an estimated fair value of $2.2 million to the 2009 Warrants. As required by the 2009 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the six months ended June 30, 2014, 35,000 2009 Warrants were exercised for net proceeds of approximately $0.1 million. The 2009 Warrants had a five-year term which expired on June 15, 2014. The remaining liability after warrant exercises was credited to pre-tax derivative instrument income.

In May 2012, the Company completed the sale of 1.0 million shares of its common stock and the issuance of warrants to purchase 0.3 million common shares (the “2012 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $21.5 million, with net cash proceeds after related expenses from this transaction of approximately $21.1 million. Of those proceeds, the Company allocated an estimated fair value of $3.4 million to the 2012 Warrants. As required by the 2012 Warrant agreement, the exercise price of the warrants was adjusted following the Company’s October 2013 sale of common stock and warrants. At June 30, 2014, the 2012 Warrants were exercisable at $2.56 per share with approximately 260,000 warrants outstanding. The 2012 Warrants have a three-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. During the six months ended June 30, 2014, approximately 13,000 2012 Warrants were exercised for net proceeds of approximately $34,000.

In October 2013, the Company completed the sale of 1.3 million shares of its common stock and the issuance of warrants to purchase 0.6 million common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The 2013 Warrants became exercisable on April 30, 2014 and at June 30, 2014, the 2013 Warrants were exercisable at $7.04 per share with 0.6 million warrants outstanding. The 2013 Warrants have a five-year term. The shares and warrants were issued pursuant to an effective registration statement on Form S-3. There were no 2013 Warrants exercised during the six months ended June 30, 2014.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 187,500, and 406,250 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award.

A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for the six months ended June 30, 2014 is as follows:

	Stock Option Activity under the Plans
	Stock Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2013		252,158		$	4.80 — $248.64	$	57.90		7.36
Granted		—			—		—
Forfeited		(52,303	)	$	5.92 — $248.64		75.99
Expired		(625	)	$	58.56 — $58.56		58.56
Outstanding at June 30, 2014		199,230		$	4.80 — $248.64	$	53.16		7.08

For the three and six months ended June 30, 2014, the Company recognized compensation expense of approximately $0.1 million and $0.3 million, respectively, relating to stock options granted to employees. For the three and six months ended June 30, 2013, the Company recognized compensation expense of approximately $0.1 million and $0.6 million, respectively, relating to stock options granted to employees.

There were no options granted during the six months ended June 30, 2014. The estimated fair value of each option award granted during the six month period ended June 30, 2013 was determined on the date of grant using an option pricing model with the following assumptions:

	Six months ended June 30, 2013
Dividend yield	None
Expected volatility		86.16% — 93.68%
Weighted average volatility		86.21%
Risk-free interest rates		0.99% — 1.36%
Expected life (in years)		6.8

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during the second half of 2012 and thereafter is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized at that time because the Company did not yet have sufficient historical experience from which to estimate the period.

Restricted stock activity for the six months ended June 30, 2014 is as follows:

	Restricted Stock Activity under the Plans
	Restricted Stock			Weighted Average Grant Date Fair Value
Non-vested at December 31, 2013		20,347		$	16.84
Granted		—			—
Vested		(17,233	)		12.70
Forfeited		(393	)		38.24
Non-vested at June 30, 2014		2,721		$	39.98

For the three and six months ended June 30, 2014, the Company recognized compensation expense of approximately $0.02 million and $0.06 million, respectively, related to restricted stock granted to employees. For the three and six months ended June 30, 2013, the Company recognized compensation expense of approximately $0.1 million and $0.2 million, respectively, related to restricted stock granted to employees.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Fair Value Measurements

6 Months Ended

Jun. 30, 2014

Fair Value Measurements [Abstract]

Fair Value Measurements

(8)	Fair Value Measurements

Derivative Warrant Liability

As disclosed in Note 7 Stockholders’ Equity of these Condensed Consolidated Financial Statements, the Company allocated part of the proceeds of public offerings in 2009, 2012 and 2013 of the Company’s common stock to warrants issued in connection with those transactions. The valuation of the warrants was determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrants should be classified as liabilities and has accounted for them as derivative instruments in accordance with ASC 815. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the three and six months ended June 30, 2014, the Company recorded pre-tax derivative warrant income of $1.3 million and $1.1 million, respectively. The resulting derivative warrant liabilities totaled $1.1 million at June 30, 2014. In the event of a hypothetical 10% increase in the market price of our common shares on which the June 30, 2014 valuation was based, the value of the derivative liability would have increased by $0.2 million. Management expects that the warrants will either be exercised or expire worthless. The fair value of the warrants at June 30, 2014 was determined by using an option pricing model with the following assumptions:

	2013 Warrants		2012 Warrants
Expected volatility		94.18%		111.35%
Risk-free interest rates		1.34%		0.11%
Expected life (in years)		4.33		0.92

Money Market Funds

The Company has determined that the inputs associated with the fair value determination of its money market funds are based on quoted prices (unadjusted) and, as a result, the investments have been classified within Level 1 of the fair value hierarchy.

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2014, aggregated by the level in the fair value hierarchy within which those measurements fall.

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1			Level 2			Level 3			Balance at June 30, 2014
Assets
Money market funds		$	1,945		$	—		$	—		$	1,945
Liabilities
Warrant liability		$	—		$	—		$	1,075		$	1,075

The table below presents the activity within Level 3 of the fair value hierarchy for the six months ended June 30, 2014:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Warrant Liability
Beginning balance as of December 31, 2013	$	2,310
Total change in the fair value of the liability included in earnings, including warrant expirations		(1,092	)
Fair value of warrants exercised		(143	)
Ending balance as of June 30, 2014	$	1,075

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Net Loss per Common Share

6 Months Ended

Jun. 30, 2014

Net Loss per Common Share [Abstract]

Net Loss per Common Share

(9)	Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share.

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the three and six month periods ended June 30, 2014 and 2013 are as follows:

	Three months ended June 30,						Six months ended June 30,
(in thousands, except share data)	2014			2013			2014			2013
Net loss – basic	$	(4,600	)	$	(5,482	)	$	(9,878	)	$	(18,328	)
Adjustment for gain on warrant derivative liability		(356	)		—			(363	)		—
Net loss – diluted	$	(4,956	)	$	(5,482	)	$	(10,241	)	$	(18,328	)

Weighted average shares outstanding – basic		9,426,169			6,023,785			9,363,123			5,683,380
Adjustment for warrant exercises		54,764			—			99,594			—
Weighted average shares outstanding – diluted		9,480,933			6,023,785			9,462,717			5,683,380

Net loss per share – basic	$	(0.49	)	$	(0.91	)	$	(1.06	)	$	(3.22	)
Net loss per share – diluted	$	(0.52	)	$	(0.91	)	$	(1.08	)	$	(3.22	)

The following potentially dilutive securities were excluded from the computation of earnings per share as of June 30, 2014 and 2013 because their effects would be anti-dilutive:

	June 30,
	2014		2013
Stock options		199,230		323,417
Unvested restricted shares		2,721		24,797
Warrants		589,500		339,994
Total		791,451		688,208

Taxes

6 Months Ended

Jun. 30, 2014

Taxes [Abstract]

Taxes

(10)

Taxes

As discussed in Note 13 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, international tax authorities, or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company’s tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2014

Commitments and Contingencies [Abstract]

Commitments and Contingencies

(11)	Commitment and Contingencies

The Company is a party to several legal proceedings. Refer to Part II, Item 1 Legal Proceedings in this Quarterly Report on Form 10-Q for more information.

Subsequent Events

6 Months Ended

Jun. 30, 2014

Subsequent Events [Abstract]

Subsequent Events

(12)	Subsequent Events

The Company completed an evaluation of the impact of any subsequent events through the date financial statements were issued and determined there were no other subsequent events requiring disclosure in or adjustment to these financial statements.

General (Policies)	6 Months Ended
General (Policies)	Jun. 30, 2014
General [Abstract]
Basis of Presentation	Basis of Presentation These interim Condensed Consolidated Financial Statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim Condensed Consolidated Financial Statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended June 30, 2014 and 2013; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, which permits an entity to release cumulative translation adjustments into net income when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business within a foreign entity. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided, or, if a controlling financial interest is no longer held. The revised standard became effective for fiscal years beginning after December 15, 2013. The Company adopted this guidance effective January 1, 2014. The Company’s adoption of this standard did not have a material impact on its consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company expects to adopt this guidance when effective, and the impact on our financial statements is not currently estimable. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is evaluating the potential impacts of the new standard on its existing stock-based compensation plans.

Inventories (Tables)

6 Months Ended

Jun. 30, 2014

Inventories [Abstract]

Schedule of inventories

Inventories consist of the following:

(in thousands)	June 30, 2014		December 31, 2013
Raw materials	$	196	$	249
Work-in-process		295		364
Finished goods		109		106
Total inventory	$	600	$	719

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following:

(in thousands)	June 30, 2014		December 31, 2013
Kits for clinical use	$	327	$	287
Insurance premiums		322		407
Professional fees		27		377
Income tax credits receivable		18		326
Other¹		158		314
Total prepaid expenses and other current assets	$	852	$	1,711

¹ Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at June 30, 2014 and December 31, 2013.

Property, Plant, and Equipment (Tables)

6 Months Ended

Jun. 30, 2014

Property, Plant, and Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consist of the following:

(in thousands)	June 30, 2014			December 31, 2013
Enterprise hardware and software	$	2,009		$	2,143
Leaseholds		1,667			1,749
Equipment		1,421			1,552
Furniture		957			957
Buildings and land		603			603
Property, plant and equipment, gross		6,657			7,004
Accumulated depreciation		(4,236	)		(3,935	)
Property, plant and equipment, net	$	2,421		$	3,069

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2014

Accrued Expenses [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:

(in thousands)	June 30, 2014		December 31, 2013
Compensation, excluding taxes	$	2,470	$	1,866
Deferred rent		315		485
Professional fees		224		360
Short-term portion of lease restructuring		209		–
Other¹		869		1,029
Total accrued expenses	$	4,087	$	3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at June 30, 2014 and December 31, 2013.

Restructuring Expenses (Tables)

6 Months Ended

Jun. 30, 2014

Restructuring Expenses [Abstract]

Schedule of restructuring and related costs

The following table provides the year-to-date activity of the Company’s restructuring reserves as of June 30, 2014:

(in thousands)	Employee Costs			Operating Lease
Reserve balance as of December 31, 2013	$	2,019		$	–
Charges		722			855
Payments / utilizations		(1,287	)		–
Reserve balance as of June 30, 2014	$	1,454		$	855

Stockholders Equity (Tables)

6 Months Ended

Jun. 30, 2014

Stockholders Equity [Abstract]

Stock option activity

	Stock Option Activity under the Plans
	Stock Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2013		252,158		$	4.80 — $248.64	$	57.90		7.36
Granted		—			—		—
Forfeited		(52,303	)	$	5.92 — $248.64		75.99
Expired		(625	)	$	58.56 — $58.56		58.56
Outstanding at June 30, 2014		199,230		$	4.80 — $248.64	$	53.16		7.08

Assumptions used to determine the fair value of stock options

	Six months ended June 30, 2013
Dividend yield	None
Expected volatility		86.16% — 93.68%
Weighted average volatility		86.21%
Risk-free interest rates		0.99% — 1.36%
Expected life (in years)		6.8

Restricted stock activity

Restricted stock activity for the six months ended June 30, 2014 is as follows:

	Restricted Stock Activity under the Plans
	Restricted Stock			Weighted Average Grant Date Fair Value
Non-vested at December 31, 2013		20,347		$	16.84
Granted		—			—
Vested		(17,233	)		12.70
Forfeited		(393	)		38.24
Non-vested at June 30, 2014		2,721		$	39.98

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2014

Fair Value Measurements [Abstract]

Schedule of fair value of the warrants

The fair value of the warrants at June 30, 2014 was determined by using an option pricing model with the following assumptions:

	2013 Warrants		2012 Warrants
Expected volatility		94.18%		111.35%
Risk-free interest rates		1.34%		0.11%
Expected life (in years)		4.33		0.92

Assets and liabilities measured at fair value on a recurring basis

	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1			Level 2			Level 3			Balance at June 30, 2014
Assets
Money market funds		$	1,945		$	—		$	—		$	1,945
Liabilities
Warrant liability		$	—		$	—		$	1,075		$	1,075

Fair value measurements using significant unobservable inputs

The table below presents the activity within Level 3 of the fair value hierarchy for the six months ended June 30, 2014:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Warrant Liability
Beginning balance as of December 31, 2013	$	2,310
Total change in the fair value of the liability included in earnings, including warrant expirations		(1,092	)
Fair value of warrants exercised		(143	)
Ending balance as of June 30, 2014	$	1,075

Net Loss per Common Share (Tables)

6 Months Ended

Jun. 30, 2014

Net Loss per Common Share [Abstract]

Calculation of net loss and number of shares used to compute basic and diluted earnings per share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the three and six month periods ended June 30, 2014 and 2013 are as follows:

	Three months ended June 30,						Six months ended June 30,
(in thousands, except share data)	2014			2013			2014			2013
Net loss – basic	$	(4,600	)	$	(5,482	)	$	(9,878	)	$	(18,328	)
Adjustment for gain on warrant derivative liability		(356	)		—			(363	)		—
Net loss – diluted	$	(4,956	)	$	(5,482	)	$	(10,241	)	$	(18,328	)

Weighted average shares outstanding – basic		9,426,169			6,023,785			9,363,123			5,683,380
Adjustment for warrant exercises		54,764			—			99,594			—
Weighted average shares outstanding – diluted		9,480,933			6,023,785			9,462,717			5,683,380

Net loss per share – basic	$	(0.49	)	$	(0.91	)	$	(1.06	)	$	(3.22	)
Net loss per share – diluted	$	(0.52	)	$	(0.91	)	$	(1.08	)	$	(3.22	)

Anti-dilutive Securities Excluded from the Computation of Earnings per Share

The following potentially dilutive securities were excluded from the computation of earnings per share as of June 30, 2014 and 2013 because their effects would be anti-dilutive:

	June 30,
	2014		2013
Stock options		199,230		323,417
Unvested restricted shares		2,721		24,797
Warrants		589,500		339,994
Total		791,451		688,208

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$ 196	$ 249
Work-in-process	295	364
Finished goods	109	106
Total inventory	$ 600	$ 719

Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2014

Dec. 31, 2013

Prepaid expenses and other current assets [Abstract]

Kits for clinical use

$ 327

$ 287

Insurance premiums

322

407

Professional fees

377

Income tax credits receivable

326

Other

^[1]

158

314

Total prepaid expenses and other current assets

$ 852

$ 1,711

Maximum percentage of prepaid expenses and other current assets (in hundredths)

5.00%

[1]	Other consists of various prepaid expenses and other current assets with no individual item accounting for more than 5% of the total balance at June 30, 2014 and December 31, 2013.

Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 6,657		$ 6,657		$ 7,004
Accumulated depreciation	(4,236)		(4,236)		(3,935)
Property, plant and equipment, net	2,421		2,421		3,069
Depreciation expense	300	$ 300	499	$ 604
Enterprise Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,009		2,009		2,143
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,667		1,667		1,749
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,421		1,421		1,552
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	957		957		957
Buildings and Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 603		$ 603		$ 603

Accrued Expenses (Details) - USD ($)
$ in Thousands

Jun. 30, 2014

Dec. 31, 2013

Accrued Expenses [Abstract]

Compensation, excluding taxes

$ 2,470

$ 1,866

Deferred rent

315

485

Professional fees

224

360

Short-term portion of lease restructuring

209

Other

^[1]

869

1,029

Total accrued expenses

$ 4,087

$ 3,740

Maximum percentage of current liabilities accrued (in hundredths)

5.00%

Percentage of current annual salary as cash retention bonus (in hundredths)

50.00%

[1]	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at June 30, 2014 and December 31, 2013.

Restructuring Expenses (Details) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended	18 Months Ended
Restructuring Expenses (Details) $ in Thousands	Jun. 30, 2014 USD ($) Employee	Jun. 30, 2014 USD ($)	Dec. 31, 2013 USD ($) Employee	Jun. 30, 2014 USD ($) Employee
Restructuring Cost and Reserve [Line Items]
Leasehold improvements written off		$ 50
Operating Lease [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance		0
Charges		855
Restructuring expenses paid		0
Restructuring reserve balance	$ 855	855	$ 0	$ 855
Employee Costs [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance		2,019
Charges		722
Restructuring expenses paid		(1,287)
Restructuring reserve balance	1,454	$ 1,454	$ 2,019	1,454
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Outstanding lease term		81 months
Contractual Obligation	3,600	$ 3,600		3,600
Sub-lease revenue		2,600
Accrued Expenses [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance	1,400	1,400		1,400
Other non-current liabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance	$ 100	100		$ 100
Operating Expense [Member]
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated \| Employee	7		50	57
Severance costs			$ 4,800
Selling, General and Administrative Expenses [Member] \| Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Contract termination costs related to sub-lease		$ 150

Stockholders Equity (Details) - USD ($)	1 Months Ended			3 Months Ended				6 Months Ended		12 Months Ended
Stockholders Equity (Details) - USD ($)	Oct. 31, 2013	May 31, 2012	Jun. 30, 2009	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Stock Issuances [Abstract]
Reverse Stock Split Ratio				one-for- sixteen (1:16)		one-for- sixteen (1:16)			one-for- sixteen (1:16)	one-for- sixteen (1:16)
Common stock, shares authorized (in shares)				170,000,000				170,000,000		170,000,000
Common stock, par value (in dollars per share)				$ 0.01				$ 0.01		$ 0.01
Common stock sold through the program (in shares)	1,300,000	1,000,000	100,000
Warrant [Abstract]
Proceeds from issuance of private placement	$ 7,500,000	$ 21,500,000	$ 3,000,000
Net proceeds from issuance of private placement	$ 6,900,000	$ 21,100,000	$ 2,700,000
Stock Incentive Plans [Abstract]
Recognized compensation expense								$ 257,000	$ 571,000
Restricted stock compensation expense								$ 60,000	241,000
Maximum [Member]
Stock Issuances [Abstract]
Reverse Stock Split Ratio								one-for- sixteen (1:16)
2004 Stock Incentive Plan [Member]
Stock Incentive Plans [Abstract]
Shares reserved for the issuance (in shares)				187,500				187,500
2009 Stock Incentive Plan [Member]
Stock Incentive Plans [Abstract]
Shares reserved for the issuance (in shares)				406,250				406,250
Stock Options [Member]
Stock Incentive Plans [Abstract]
Maximum term of options								10 years
Recognized compensation expense				$ 100,000		$ 100,000		$ 300,000	600,000
Restricted Stock [Member]
Stock Incentive Plans [Abstract]
Restricted stock compensation expense				$ 20,000		$ 100,000		$ 60,000	200,000
2012 Warrants [Member]
Warrant [Abstract]
Warrants issued (in shares)		300,000
Estimated fair value allocated to warrants issued		$ 3,400,000
Warrants exercisable per share price (in dollars per share)				$ 2.56				$ 2.56
Number of warrants outstanding (in shares)				260,000				260,000
Term period for warrants								3 years
Warrants Exercised (in shares)								13,000
Net proceeds from exercise of warrants								$ 34,000
2009 Warrants [Member]
Warrant [Abstract]
Warrants issued (in shares)			100,000
Estimated fair value allocated to warrants issued			$ 2,200,000
Term period for warrants								5 years
Warrants Exercised (in shares)								35,000
Net proceeds from exercise of warrants								$ 100,000
2013 Warrants [Member]
Warrant [Abstract]
Warrants issued (in shares)	600,000
Estimated fair value allocated to warrants issued	$ 1,900,000
Warrants exercisable per share price (in dollars per share)				$ 7.04				$ 7.04
Term period for warrants								5 years
Sales Agreement March 2013 [Member] \| Cowen and Company, LLC [Member]
Stock Issuances [Abstract]
Common stock, par value under sales agreement (in dollars per share)				$ 0.01				$ 0.01
Proceeds from issuance of common stock					$ 4,400,000					$ 5,000,000
Proceeds of common stock issued, net of related expenses					$ 4,400,000					$ 4,800,000
Common stock sold through the program (in shares)					1,000,000					1,000,000
Aggregate proceeds from sale of common stock under equity offering program, maximum				$ 50,000,000				$ 50,000,000
Aggregate proceeds from sale of common stock under equity offering program, remaining				40,400,000				40,400,000
CEFF [Member] \| Terrapin Opportunity, L.P. [Member]
Stock Issuances [Abstract]
Proceeds from issuance of common stock								11,100,000
Proceeds of common stock issued, net of related expenses								$ 10,800,000
Common stock sold through the program (in shares)								500,000
Amount to be purchased by party under agreement								$ 35,000,000
Term of purchase agreement								24 months
Amount Available Under Committed Equity Financing Facility				$ 23,900,000				$ 23,900,000
Sales Agreement December 2011 [Member] \| Cowen and Company, LLC [Member]
Stock Issuances [Abstract]
Common stock, par value under sales agreement (in dollars per share)										$ 0.01
Proceeds from issuance of common stock									20,900,000
Proceeds of common stock issued, net of related expenses									$ 20,800,000
Common stock sold through the program (in shares)							14,200,000
Aggregate proceeds from sale of common stock under equity offering program, maximum										$ 39,800,000

Stockholders Equity, Stock Incentive Plans (Details) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Stock Options [Member]
Stock Options [Roll Forward]
Outstanding at December 31, 2013 (in shares)	252,158
Granted (in shares)	0
Forfeited (in shares)	(52,303)
Expired (in shares)	(625)
Outstanding at June 30, 2014 (in shares)	199,230		252,158
Stock Options, Exercise Price per Share [Roll Forward]
Granted (in dollars per share)	$ 0
Weighted Average Exercise Price [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	57.90
Granted (in dollars per share)	0
Forfeited (in dollars per share)	75.99
Expired (in dollars per share)	58.56
Outstanding at June 30, 2014 (in dollars per share)	$ 53.16		$ 57.90
Weighted Average Remaining Life [Abstract]
Weighted Average Remaining Life	7 years 29 days		7 years 4 months 10 days
Assumptions used to determine the fair value of stock options [Abstract]
Dividend yield (in hundredths)		0.00%
Weighted average volatility (in hundredths)		86.21%
Expected life		6 years 9 months 18 days
Stock Options [Member] \| Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	$ 4.80
Forfeited (in dollars per share)	5.92
Expired (in dollars per share)	58.56
Outstanding at June 30, 2014 (in dollars per share)	4.80		$ 4.80
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)		86.16%
Risk-free interest rates (in hundredths)		0.99%
Stock Options [Member] \| Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	248.64
Forfeited (in dollars per share)	248.64
Expired (in dollars per share)	58.56
Outstanding at June 30, 2014 (in dollars per share)	$ 248.64		$ 248.64
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)		93.68%
Risk-free interest rates (in hundredths)		1.36%
Restricted Stock [Member]
Restricted Stock [Roll Forward]
Outstanding at December 31, 2013 (in shares)	20,347
Granted (in shares)	0
Vested (in shares)	(17,233)
Forfeited (in shares)	(393)
Outstanding at June 30, 2014 (in shares)	2,721		20,347
Weighted Average Grant Date Fair Value [Roll Forward]
Outstanding at December 31, 2013 (in dollars per share)	$ 16.84
Granted (in dollars per share)	0
Vested (in dollars per share)	12.70
Forfeited (in dollars per share)	38.24
Outstanding at June 30, 2014 (in dollars per share)	$ 39.98		$ 16.84

Fair Value Measurements (Details) $ in Thousands	3 Months Ended	6 Months Ended
Fair Value Measurements (Details) $ in Thousands	Jun. 30, 2014 USD ($)	Jun. 30, 2014 USD ($) Input
Derivative warrant liability [Abstract]
Number of inputs used for valuation of warrants \| Input		6
Pre-tax derivative instrument expense	$ 1,300	$ 1,100
Hypothetical change in market price of common shares (in hundredths)		10.00%
Impact of the hypothetical change in market price of common shares on derivative liability		$ 200
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance as of December 31, 2013		2,310
Total change in the fair value of the liability included in earnings, including warrant expairations		(1,092)
Fair value of warrants exercised		(143)
Ending balance as of June 30, 2014	1,075	$ 1,075
2012 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)		111.35%
Risk-free interest rates (in hundredths)		0.11%
Expected life (in years)		11 months 1 day
2013 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)		94.18%
Risk-free interest rates (in hundredths)		1.34%
Expected life (in years)		4 years 3 months 29 days
Recurring [Member] \| Warrant liability [Member]
Liabilities [Abstract]
Total Liabilities	1,075	$ 1,075
Recurring [Member] \| Warrant liability [Member] \| Level 1 [Member]
Liabilities [Abstract]
Total Liabilities	0	0
Recurring [Member] \| Warrant liability [Member] \| Level 2 [Member]
Liabilities [Abstract]
Total Liabilities	0	0
Recurring [Member] \| Warrant liability [Member] \| Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	1,075	1,075
Recurring [Member] \| Money market funds [Member]
Assets [Abstract]
Total Assets	1,945	1,945
Recurring [Member] \| Money market funds [Member] \| Level 1 [Member]
Assets [Abstract]
Total Assets	1,945	1,945
Recurring [Member] \| Money market funds [Member] \| Level 2 [Member]
Assets [Abstract]
Total Assets	0	0
Recurring [Member] \| Money market funds [Member] \| Level 3 [Member]
Assets [Abstract]
Total Assets	$ 0	$ 0